JPH0220068B2 - - Google Patents
Info
- Publication number
- JPH0220068B2 JPH0220068B2 JP57139110A JP13911082A JPH0220068B2 JP H0220068 B2 JPH0220068 B2 JP H0220068B2 JP 57139110 A JP57139110 A JP 57139110A JP 13911082 A JP13911082 A JP 13911082A JP H0220068 B2 JPH0220068 B2 JP H0220068B2
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- blocking
- self
- calibrator
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000005962 receptors Human genes 0.000 claims description 43
- 108020003175 receptors Proteins 0.000 claims description 43
- 239000003446 ligand Substances 0.000 claims description 30
- 230000000903 blocking effect Effects 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 15
- 239000011715 vitamin B12 Substances 0.000 claims description 14
- 239000007790 solid phase Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 239000011521 glass Substances 0.000 claims description 11
- 239000007791 liquid phase Substances 0.000 claims description 11
- 239000013060 biological fluid Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 239000013641 positive control Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 239000000941 radioactive substance Substances 0.000 claims 1
- 238000004092 self-diagnosis Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 10
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 10
- 230000002285 radioactive effect Effects 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 229940029329 intrinsic factor Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical class [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ãèªå·±é®ææäœãæ€ç¥ããæ¹æ³ãšã該
æ¹æ³ã«çšããããè©Šè¬ãããã«é¢ããã
æ¹æ³ã«çšããããè©Šè¬ãããã«é¢ããã
å€ãã®éåžžã®çç©åŠççžäºäœçšã«éããŠã¯ãç
äœå ã®åçš®ã®ç©è³ªããã®çµåãµã€ãïŒçµåéšäœïŒ
ãä»ããŠäºã«çµåããªããã°ãªããªããæã«ã¯ã
é®ææäœïŒããããèªå·±é®ææäœïŒauto
blocking antibodyïŒïŒãçæããããšã«ãã€ãŠã
åäœã®å ç«ã·ã¹ãã ãããããã®ç©è³ªã®ïŒã€ïŒçµ
åå€ãªããã¯ã¬ã»ãã¿èçœè³ªã§ããããšãå€ãïŒ
ã«å¯Ÿããèªå·±å ç«ãåµãåºãããã®é®ææäœã¯ã
ã¬ã»ãã¿äžã®çžè£çµåãµã€ãã«ç«¶åçã«åžåŒãã
ãããããã€ãŠãã¬ã»ãã¿ãæ¬æ¥åå¿ãã¹ãçžè£
ç©è³ªïŒãããããªã¬ã³ãïŒligandïŒã§ããããè
çœè³ªã§ããããšãå€ãïŒã«å¯Ÿããçµåãµã€ããæž
å°ããããšã«ãªãã
äœå ã®åçš®ã®ç©è³ªããã®çµåãµã€ãïŒçµåéšäœïŒ
ãä»ããŠäºã«çµåããªããã°ãªããªããæã«ã¯ã
é®ææäœïŒããããèªå·±é®ææäœïŒauto
blocking antibodyïŒïŒãçæããããšã«ãã€ãŠã
åäœã®å ç«ã·ã¹ãã ãããããã®ç©è³ªã®ïŒã€ïŒçµ
åå€ãªããã¯ã¬ã»ãã¿èçœè³ªã§ããããšãå€ãïŒ
ã«å¯Ÿããèªå·±å ç«ãåµãåºãããã®é®ææäœã¯ã
ã¬ã»ãã¿äžã®çžè£çµåãµã€ãã«ç«¶åçã«åžåŒãã
ãããããã€ãŠãã¬ã»ãã¿ãæ¬æ¥åå¿ãã¹ãçžè£
ç©è³ªïŒãããããªã¬ã³ãïŒligandïŒã§ããããè
çœè³ªã§ããããšãå€ãïŒã«å¯Ÿããçµåãµã€ããæž
å°ããããšã«ãªãã
çæããåŸãèªå·±é®ææäœç³»ãšããŠããç¥ãã
ãäŸã®äžã€ã¯ãå å æ§å åãšã³ãã©ãã³ïŒãã¿ã
ã³B12ïŒãšã®éã®çžäºäœçšã§ãããå å æ§å å
ïŒintrinsic factorïŒãšã¯ãèè žç®¡ãä»ããŠãã¿ã
ã³B12ãåžåããã®ã«å¯äžããç³èçœè³ªã§ããã
æ³šå ¥åŸããã¿ãã³B12ã¯ç¹å®ã®ã¬ã»ãã¿ãµã€ãã
ä»ããŠå å æ§å åãšçµåããåŸãããè€åäœã¯è©²
è€åäœã®ã¬ã»ãã¿ãä»ããŠèè žç®¡ã«åžåãããã
ãäŸã®äžã€ã¯ãå å æ§å åãšã³ãã©ãã³ïŒãã¿ã
ã³B12ïŒãšã®éã®çžäºäœçšã§ãããå å æ§å å
ïŒintrinsic factorïŒãšã¯ãèè žç®¡ãä»ããŠãã¿ã
ã³B12ãåžåããã®ã«å¯äžããç³èçœè³ªã§ããã
æ³šå ¥åŸããã¿ãã³B12ã¯ç¹å®ã®ã¬ã»ãã¿ãµã€ãã
ä»ããŠå å æ§å åãšçµåããåŸãããè€åäœã¯è©²
è€åäœã®ã¬ã»ãã¿ãä»ããŠèè žç®¡ã«åžåãããã
æªæ§è²§è¡ã«ãããŠã¯ãå
å æ§å åãäœãäžã€å
ç§ããèœåã次第ã«è¡°éãæåŸã«ã¯æ¶æ» ããŠããŸ
ããæªæ§è²§è¡ãšèªå·±å ç«æäœïŒç¹ã«ãå å æ§å å
é®ææäœïŒã®ååšãšã®éã«ã¯éåžžã«å¯æ¥ãªé¢ä¿ã
ããã
ç§ããèœåã次第ã«è¡°éãæåŸã«ã¯æ¶æ» ããŠããŸ
ããæªæ§è²§è¡ãšèªå·±å ç«æäœïŒç¹ã«ãå å æ§å å
é®ææäœïŒã®ååšãšã®éã«ã¯éåžžã«å¯æ¥ãªé¢ä¿ã
ããã
äžè¿°ã®ãããªç¶æ³ã«ãããŠã¯ãé®ææäœãäŸã
ã°ãå å æ§å åé®ææäœïŒä»¥äžãIFïŒintrinsic
factorïŒé®æãµã€ãæäœãšç§°ããïŒã®ååšãå°ãª
ããšãå®æ§çã«ç¥ãããšãã§ãããšããããŠæçš
ã§ãããïŒãªããå å æ§å åã¯ãå°ãªããšãïŒçš®
é¡ã®çµåãµã€ããå«æãããšèããããŠãããã
ãã®ãã¡ã®ïŒçš®é¡ã®ã¿ããã¿ãã³B12ãšè€åäœã
圢æããã®ã«é¢äžãããïŒ å å æ§å åâãã¿ãã³B12ã®åé¡ã«é¢é£ããŠã
åŸæ¥æè¡ã«ãããŠã¯ãIFé®ææäœã®ååšãæ€ç¥
ããã®ã«ã©ãžãªã¢ãã»ã€ïŒæŸå°æšèæ€å®ïŒæ³ãçš
ããããšãæ瀺ãããŠããããããã®åŸæ¥æè¡ã¯
ãã¹ãŠæº¶è§£æ段ãçšãããã®ã§ãããããªãã¡ã
åå¿è©Šè¬ãå šãŠæº¶æ¶²ç¶æ ã«ããããå°ãªããšãã
液ç¶åªäœäžã«èªç±ã«æžæ¿ããããã®ã§ããããã
ããŠãåœç¶ã®ããšã§ããããIFé®ææäœãå©çš
ããŠãæšèä»ãããïŒããªãã¡ãæŸå°æ§ã®ïŒãã¿
ãã³B12ãå å æ§å åã«çµåããã®ã劚ããæ段
ãçšãããäžè¬çã«ã¯ãå å æ§å åïŒããªãã¡ã
å å æ§å åãå«æããè液ïŒãæ£è ã®çäœæ¶²è©Šæ
ïŒäŸãã°ãè¡æž ïŒãšæ··åãããããåŸã該混åç©
ã«ãæšèä»ããããã¿ãã³B12ãïŒéå°ã«ïŒæ·»å
ããã次ãã§ãæšèä»ããããã¿ãã³B12ã®éé¢
ç¶æ ã®ãã®ãããçµåããæšèä»ãã¿ãã³B12ã
åé¢ããããšãå¿ èŠãšãªãããã®ãããªåé¢æ段
ãšããŠãéæãã²ã«éã掻æ§çåžåãããã³ãª
ã³é žãžã«ã³ãã«ã²ã«åžåãæ瀺ãããŠããããã®
ããã«ç ©éã§æéã®ãããåé¢æ段ãå¿ èŠã§ãã
ããšã®ä»ã«ã溶解æ段ãåºç€ãšããã©ãžãªã¢ãã»
ã€æ³ã¯ãå€ãã®æ£è ã®è©Šæã«å å æ§ã®ãã¿ãã³
B12çµåå€ãååšããããšã«ããå°é£ã䌎ãªãã
ããªãã¡ãå å æ§ãã¿ãã³B12çµåå€ãèæ ®ãã
ä»å çãªå¯Ÿç §æäœãè¡ãªã€ãããè©Šæããå å æ§
ãã¿ãã³B12çµåå€ãé€å»ããæäœãå¿ èŠãšãª
ãã
ã°ãå å æ§å åé®ææäœïŒä»¥äžãIFïŒintrinsic
factorïŒé®æãµã€ãæäœãšç§°ããïŒã®ååšãå°ãª
ããšãå®æ§çã«ç¥ãããšãã§ãããšããããŠæçš
ã§ãããïŒãªããå å æ§å åã¯ãå°ãªããšãïŒçš®
é¡ã®çµåãµã€ããå«æãããšèããããŠãããã
ãã®ãã¡ã®ïŒçš®é¡ã®ã¿ããã¿ãã³B12ãšè€åäœã
圢æããã®ã«é¢äžãããïŒ å å æ§å åâãã¿ãã³B12ã®åé¡ã«é¢é£ããŠã
åŸæ¥æè¡ã«ãããŠã¯ãIFé®ææäœã®ååšãæ€ç¥
ããã®ã«ã©ãžãªã¢ãã»ã€ïŒæŸå°æšèæ€å®ïŒæ³ãçš
ããããšãæ瀺ãããŠããããããã®åŸæ¥æè¡ã¯
ãã¹ãŠæº¶è§£æ段ãçšãããã®ã§ãããããªãã¡ã
åå¿è©Šè¬ãå šãŠæº¶æ¶²ç¶æ ã«ããããå°ãªããšãã
液ç¶åªäœäžã«èªç±ã«æžæ¿ããããã®ã§ããããã
ããŠãåœç¶ã®ããšã§ããããIFé®ææäœãå©çš
ããŠãæšèä»ãããïŒããªãã¡ãæŸå°æ§ã®ïŒãã¿
ãã³B12ãå å æ§å åã«çµåããã®ã劚ããæ段
ãçšãããäžè¬çã«ã¯ãå å æ§å åïŒããªãã¡ã
å å æ§å åãå«æããè液ïŒãæ£è ã®çäœæ¶²è©Šæ
ïŒäŸãã°ãè¡æž ïŒãšæ··åãããããåŸã該混åç©
ã«ãæšèä»ããããã¿ãã³B12ãïŒéå°ã«ïŒæ·»å
ããã次ãã§ãæšèä»ããããã¿ãã³B12ã®éé¢
ç¶æ ã®ãã®ãããçµåããæšèä»ãã¿ãã³B12ã
åé¢ããããšãå¿ èŠãšãªãããã®ãããªåé¢æ段
ãšããŠãéæãã²ã«éã掻æ§çåžåãããã³ãª
ã³é žãžã«ã³ãã«ã²ã«åžåãæ瀺ãããŠããããã®
ããã«ç ©éã§æéã®ãããåé¢æ段ãå¿ èŠã§ãã
ããšã®ä»ã«ã溶解æ段ãåºç€ãšããã©ãžãªã¢ãã»
ã€æ³ã¯ãå€ãã®æ£è ã®è©Šæã«å å æ§ã®ãã¿ãã³
B12çµåå€ãååšããããšã«ããå°é£ã䌎ãªãã
ããªãã¡ãå å æ§ãã¿ãã³B12çµåå€ãèæ ®ãã
ä»å çãªå¯Ÿç §æäœãè¡ãªã€ãããè©Šæããå å æ§
ãã¿ãã³B12çµåå€ãé€å»ããæäœãå¿ èŠãšãª
ãã
æ¬çºæã®ç¹å®ã®å®æœæ
æ§ã«åŸãã°ãIFé®æãµ
ã€ãæäœã®ååšãæ€ç¥ããã®ã«åŸæ¥æè¡ã®ãããª
溶解æ段ãçšããããšã«äŒŽãªãåé¡ãå æããã
æŽã«ãä»ã®èªå·±é®ææäœãæ€ç¥ããã®ã«æçšäžè¬
çãªææ³ãæäŸãããã
ã€ãæäœã®ååšãæ€ç¥ããã®ã«åŸæ¥æè¡ã®ãããª
溶解æ段ãçšããããšã«äŒŽãªãåé¡ãå æããã
æŽã«ãä»ã®èªå·±é®ææäœãæ€ç¥ããã®ã«æçšäžè¬
çãªææ³ãæäŸãããã
ããªãã¡ãæ¬çºæã®ç®çã¯ãèªå·±é®ææäœã®å
åšãå®æ§çãŸãã¯å®éçã«æ€ç¥ããæ¹æ³ãæäŸã
ãããšã«ããã
åšãå®æ§çãŸãã¯å®éçã«æ€ç¥ããæ¹æ³ãæäŸã
ãããšã«ããã
æ¬çºæã®ä»ã®ç®çã¯ãIFé®æãµã€ãæäœã®å
åšãæ€ç¥ããæ¹æ³ãæäŸããããšã«ããã
åšãæ€ç¥ããæ¹æ³ãæäŸããããšã«ããã
æ¬çºæã®æŽã«å¥ã®ç®çã¯ãåŸæ¥æè¡ã®ããã«æº¶
解æ³ãçšããããšã«ããåé¡ãæããªããIFé®
æãµã€æäœãæ€ç¥ããæ¹æ³ãæäŸããããšã«åã
ãã
解æ³ãçšããããšã«ããåé¡ãæããªããIFé®
æãµã€æäœãæ€ç¥ããæ¹æ³ãæäŸããããšã«åã
ãã
æ¬çºæã®å¥ã®ç®çã¯ãæ£è
ã®èªå·±é®ææäœã®å
åšãå®éçãŸãã¯å®æ§çã«æ€ç¥ããã®ã«çšããã
ã蚺æçšè©Šè¬ããããæäŸããããšã«ããã
åšãå®éçãŸãã¯å®æ§çã«æ€ç¥ããã®ã«çšããã
ã蚺æçšè©Šè¬ããããæäŸããããšã«ããã
æ¬çºæã®æŽã«å¥ã®ç®çã¯ãæ£è
ã®IFé®ææäœ
ã®ååšãæ€ç¥ããã®ã«çšãããã蚺æçšè©Šè¬ãã
ããæäŸããããšã«ããã
ã®ååšãæ€ç¥ããã®ã«çšãããã蚺æçšè©Šè¬ãã
ããæäŸããããšã«ããã
æ¬çºæã®æŽã«å¥ã®ç®çã¯ãæ£è
ã®IFé®æãµã€
ãæäœã®ååšãç¥ããé©åœãªæ€éäœãå«ã蚺æçš
è©Šè¬ããããæäŸããããšã«ããã
ãæäœã®ååšãç¥ããé©åœãªæ€éäœãå«ã蚺æçš
è©Šè¬ããããæäŸããããšã«ããã
æ¬çºæãã®ä»ã®ç®çã¯ã以äžã®çºæã®è©³çŽ°ãªèª¬
æããæããã«ãªãã§ãããã
æããæããã«ãªãã§ãããã
æ¬çºæã«åŸãã°ãç¬èªã®äžååã¬ã»ãã¿ãå©çš
ãã©ãžãªã¢ãã»ã€æ³ã«ãããèªå·±é®ææäœãæ€ç¥
ãããã
ãã©ãžãªã¢ãã»ã€æ³ã«ãããèªå·±é®ææäœãæ€ç¥
ãããã
ããªãã¡ãæ¬çºæã¯ãèªå·±é®ææäœã®ååšãæ€
ç¥ããæ¹æ³ã§ãã€ãŠã (a) èªå·±é®ææäœãå«æããŠãããšèããããç
äœæ¶²è©Šæãã該æäœã«å¯Ÿããéžæçãªçµåãµã€
ããæããã€äžæŽ»æ§ïŒinanimateïŒæ äœäžã«äž
ååãããã¬ã»ãã¿ãšæ··åãïŒ (b) åèšã®å·¥çš(a)ããåŸãããæ··åç©ããååšã
ãåèšæäœã®è³ªçã«ãã¹ãŠãåèšã¬ã»ãã¿ãšçµ
åããã®ã«å åãªæ¡ä»¶äžã«å¹é€ããããšã«ã
ããåèšäžæŽ»æ§æ äœã«åèšé®ææäœãçµåãã
åºäœçžãšãåèšé®ææäœãæããªãåèšçäœæ¶²
è©Šæãããªã液äœçžãšãçãããïŒ (c) åèšæ¶²äœçžããåèšåºäœçžãåé¢ãïŒ (d) ãã®åé¢ãããåºäœçžã«ãåèšéžæççµåãµ
ã€ãã«çµåããã®æšèåãªã¬ã³ããããªã液äœ
ãæ··åãïŒ (e) åèšã¬ã»ãã¿ã®éžæççµåãµã€ãã®ãã¡åèš
é®ææäœã«çµåããŠããªããµã€ãã«åèšæšèå
ãªã¬ã³ããçµåãåŸãã«å åãªæ¡ä»¶äžã«ãã
ãŠãåèšå·¥çš(d)ã«ãã€ãŠåŸãããæ··åç©ãå¹é€
ããŠãé®ææäœããã³æšèåãªã¬ã³ãã®ãã¡å°
ãªããšãäžæ¹ãçµåããåèšäžæŽ»æ§æ äœãããª
ã第ïŒã®åºäœçžãšãæªçµåã®æšèåãªã¬ã³ãã
ããªã第ïŒã®æ¶²äœçžãšãçãããïŒ (f) åèšç¬¬ïŒã®æ¶²äœçžããåèšç¬¬ïŒã®åºäœçžãå
é¢ãïŒããã« (g) åèšç¬¬ïŒã®åºäœçžããã³ç¬¬ïŒã®æ¶²äœçžã®ãã¡
ã®å°ãªããšãäžæ¹ã«ååšããæšèåãªã¬ã³ãã®
éã枬å®ããããšãããªãæ¹æ³ã«é¢ãããã®ã§
ããã
ç¥ããæ¹æ³ã§ãã€ãŠã (a) èªå·±é®ææäœãå«æããŠãããšèããããç
äœæ¶²è©Šæãã該æäœã«å¯Ÿããéžæçãªçµåãµã€
ããæããã€äžæŽ»æ§ïŒinanimateïŒæ äœäžã«äž
ååãããã¬ã»ãã¿ãšæ··åãïŒ (b) åèšã®å·¥çš(a)ããåŸãããæ··åç©ããååšã
ãåèšæäœã®è³ªçã«ãã¹ãŠãåèšã¬ã»ãã¿ãšçµ
åããã®ã«å åãªæ¡ä»¶äžã«å¹é€ããããšã«ã
ããåèšäžæŽ»æ§æ äœã«åèšé®ææäœãçµåãã
åºäœçžãšãåèšé®ææäœãæããªãåèšçäœæ¶²
è©Šæãããªã液äœçžãšãçãããïŒ (c) åèšæ¶²äœçžããåèšåºäœçžãåé¢ãïŒ (d) ãã®åé¢ãããåºäœçžã«ãåèšéžæççµåãµ
ã€ãã«çµåããã®æšèåãªã¬ã³ããããªã液äœ
ãæ··åãïŒ (e) åèšã¬ã»ãã¿ã®éžæççµåãµã€ãã®ãã¡åèš
é®ææäœã«çµåããŠããªããµã€ãã«åèšæšèå
ãªã¬ã³ããçµåãåŸãã«å åãªæ¡ä»¶äžã«ãã
ãŠãåèšå·¥çš(d)ã«ãã€ãŠåŸãããæ··åç©ãå¹é€
ããŠãé®ææäœããã³æšèåãªã¬ã³ãã®ãã¡å°
ãªããšãäžæ¹ãçµåããåèšäžæŽ»æ§æ äœãããª
ã第ïŒã®åºäœçžãšãæªçµåã®æšèåãªã¬ã³ãã
ããªã第ïŒã®æ¶²äœçžãšãçãããïŒ (f) åèšç¬¬ïŒã®æ¶²äœçžããåèšç¬¬ïŒã®åºäœçžãå
é¢ãïŒããã« (g) åèšç¬¬ïŒã®åºäœçžããã³ç¬¬ïŒã®æ¶²äœçžã®ãã¡
ã®å°ãªããšãäžæ¹ã«ååšããæšèåãªã¬ã³ãã®
éã枬å®ããããšãããªãæ¹æ³ã«é¢ãããã®ã§
ããã
æ¬çºæã®å¥œãŸããå®æœæ
æ§ã«ãããŠã¯ãã¬ã»ã
ã¿ã¯èçœè³ªã§ããã
ã¿ã¯èçœè³ªã§ããã
æ¬çºæã®ä»ã®å¥œãŸããå®æœæ
æ§ã«ãããŠã¯ãã¬
ã»ãã¿ã¯å å æ§å åã§ãããæšèä»ãããããªã¬
ã³ãã¯ãã¿ãã³B12ã§ããã
ã»ãã¿ã¯å å æ§å åã§ãããæšèä»ãããããªã¬
ã³ãã¯ãã¿ãã³B12ã§ããã
æŽã«ãæ¬çºæã®å¥ã®å¥œãŸããå®æœæ
æ§ã«ãããŠ
ã¯ãè©Šéšæäœã«éããŠã¯ãé°æ§ã®æ€éçšå¯Ÿç §ç©ã
ãã³éœæ§ã®æ€éçšå¯Ÿç §ç©ãçšããããã
ã¯ãè©Šéšæäœã«éããŠã¯ãé°æ§ã®æ€éçšå¯Ÿç §ç©ã
ãã³éœæ§ã®æ€éçšå¯Ÿç §ç©ãçšããããã
æ¬çºæã®ä»ã®å¥œãŸããå®æœæ
æ§ã«ãããŠã¯ãäž
掻æ§æ äœãšããŠçšããããã¬ã©ã¹ããŒãºãšã¬ã»ã
ã¿ãå ±æçµåãããã
掻æ§æ äœãšããŠçšããããã¬ã©ã¹ããŒãºãšã¬ã»ã
ã¿ãå ±æçµåãããã
äžè¿°ããããã«ãæ¬çºæã¯ãå®æ§çãŸãã¯å®é
çã«ãèªå·±é®ææäœã®ååšãç¥ãã®ã«æçšã§ã
ããæ¬çºæã¯ãIFé®æãµã€ãæäœãåæããã
ãšãäŸã«ããŠèª¬æãããŠããããã¬ã»ãã¿ãç©ç
çããã³ïŒãŸãã¯ïŒååŠçã«äžæŽ»æ§æ äœã«åºå®ã
ãããŸããæšèä»ããªã¬ã³ãã該æ¯æäœã«å¹é€ã
ãåŸãéãã¯ãä»ã®èªå·±é®æãµã€ãæäœãäŸã
ã°ãã°ã¬ãŒãã¹æ°ç ïŒç²ç¶ç·åºæ¿ãã«ã¢ã³çšã®èª
å·±é®ææäœã®ååšãç¥ãïŒãã¢ãžãœã³æ°ç çã«ã
ããæäœãåæããã®ã«ãçããæçšã§ãããšè
ããããããŸããæ¬çºæã¯ãäžè¿°ã®ãããªåæã
è¡ãªãæ¹æ³ã®ã¿ãªããã該æ¹æ³ã«çšããããè©Šè¬
ããããæäŸãããã®ã§ããããã®å¥œãŸããæ æ§
ã«ãããŠã¯ãïŒçš®é¡ã®æ€éäœãå«ãŸãããŸããæ
æã«å¿ããŠãéœæ§ã®å¯Ÿç §äœãå«ãŸããŠããã
çã«ãèªå·±é®ææäœã®ååšãç¥ãã®ã«æçšã§ã
ããæ¬çºæã¯ãIFé®æãµã€ãæäœãåæããã
ãšãäŸã«ããŠèª¬æãããŠããããã¬ã»ãã¿ãç©ç
çããã³ïŒãŸãã¯ïŒååŠçã«äžæŽ»æ§æ äœã«åºå®ã
ãããŸããæšèä»ããªã¬ã³ãã該æ¯æäœã«å¹é€ã
ãåŸãéãã¯ãä»ã®èªå·±é®æãµã€ãæäœãäŸã
ã°ãã°ã¬ãŒãã¹æ°ç ïŒç²ç¶ç·åºæ¿ãã«ã¢ã³çšã®èª
å·±é®ææäœã®ååšãç¥ãïŒãã¢ãžãœã³æ°ç çã«ã
ããæäœãåæããã®ã«ãçããæçšã§ãããšè
ããããããŸããæ¬çºæã¯ãäžè¿°ã®ãããªåæã
è¡ãªãæ¹æ³ã®ã¿ãªããã該æ¹æ³ã«çšããããè©Šè¬
ããããæäŸãããã®ã§ããããã®å¥œãŸããæ æ§
ã«ãããŠã¯ãïŒçš®é¡ã®æ€éäœãå«ãŸãããŸããæ
æã«å¿ããŠãéœæ§ã®å¯Ÿç §äœãå«ãŸããŠããã
æ¬çºæã®ææ³ã¯ãäžååããã¬ã»ãã¿ïŒæãå€
ãã¯ãäžååããã¬ã»ãã¿èçœè³ªïŒãçšããããš
ãåºç€ãšããŠãããã¬ã»ãã¿ã¯ãæ£è ã®çäœæ¶²è©Š
æã«ååšããŠããä»»æã®èªå·±é®ææäœãåžåŒãã
ããããªçµåãµã€ããæããç©è³ªã§ããããŸãã
該ã¬ã»ãã¿ã¯ãçäœå ã§ã®çç©åŠççžäºäœçšã«ã
ããŠãªã¬ã³ãã«çµåããã®ãäžè¬çã§ãããããª
ç©è³ªã§ããããšããããèªå·±é®ææäœïŒããã¯ã
æ£è ã«ãã€ãŠçæãããïŒã¯ããªã¬ã³ããšã¬ã»ã
ã¿ãšã®éã«ãããŠçäœå ã§è€åäœãçæããïŒã
ã®çæã¯ã¬ã»ãã¿âãªã¬ã³ãçµåã«çšããããã®
ã«é©ããçµåãµã€ãã®å°ãªããšã幟ã€ãã«ã¬ã»ã
ã¿ãçµåããããšã«ãã€ãŠè¡ãªãããïŒã®ã劚害
ããã
ãã¯ãäžååããã¬ã»ãã¿èçœè³ªïŒãçšããããš
ãåºç€ãšããŠãããã¬ã»ãã¿ã¯ãæ£è ã®çäœæ¶²è©Š
æã«ååšããŠããä»»æã®èªå·±é®ææäœãåžåŒãã
ããããªçµåãµã€ããæããç©è³ªã§ããããŸãã
該ã¬ã»ãã¿ã¯ãçäœå ã§ã®çç©åŠççžäºäœçšã«ã
ããŠãªã¬ã³ãã«çµåããã®ãäžè¬çã§ãããããª
ç©è³ªã§ããããšããããèªå·±é®ææäœïŒããã¯ã
æ£è ã«ãã€ãŠçæãããïŒã¯ããªã¬ã³ããšã¬ã»ã
ã¿ãšã®éã«ãããŠçäœå ã§è€åäœãçæããïŒã
ã®çæã¯ã¬ã»ãã¿âãªã¬ã³ãçµåã«çšããããã®
ã«é©ããçµåãµã€ãã®å°ãªããšã幟ã€ãã«ã¬ã»ã
ã¿ãçµåããããšã«ãã€ãŠè¡ãªãããïŒã®ã劚害
ããã
äžæŽ»æ§æ
äœã«èçœè³ªãä»ã®ã¬ã»ãã¿ç©è³ªãåºå®
ããæè¡ã¯ãæ¬æ现æžã§è©³è¿°ããå¿ èŠããªãçšæ¢
ã«é²æ©ããŠãããåçš®ã®äžæŽ»æ§ç²åãããŒãºãè¡š
é¢ïŒäŸãã°ãåæïŒææ©ïŒããªããŒãã»ã©ãã
ã¯ãç¡æ©ç²æ«ã倩ç¶ããªããŒãã»ã«ããŒã¹ãã¢ã¬
ããŒã¹çïŒã䜿çšããåŸããã奜ãŸããåºäœã¯ã¬
ã©ã¹ã§ãããäŸãã°ãç±³åœããµããŠãŒã»ããå·ã¡
ããã€ã«ãã®Corning Medical and Scientific
瀟ããå ¥æã§ãå€ãã®IMMOPHASEåææ³ã§
çšããããŠãããããªã¬ã©ã¹ç²åã§ãããããã
ã®ã¬ã©ã¹ã¯ãå€ãã®å Žåãã¢ããã·ã©ã³ã«ãã€ãŠ
åŠçããããã®å€å床ã調æŽãåŸããã®ã§ããã
ã¬ã»ãã¿ã¯ãå ±æçµåãä»ããŠåºäœã«çµåããã
ã®ãéåžžã§ããããã®éãåœè©²æè¡åéã«ãããŠ
ããç¥ãããŠããããã«ãååšããåå¿åºã«å¿ã
ãŠã¹ããŒãµéšåãçšãããããçšããããªãã€ã
ããããäŸãã°ãåœè©²æè¡åéã«ãããŠè¯ãç¥ã
ããŠããããã«ã¢ããã·ã©ã³çµåããã³ã°ã«ã¿ãŒ
ã«ã¢ã«ããããä»ããŠãå€å床ã調æŽãããã¬ã©
ã¹ç²åã«å å æ§å åãåå¿ãããããšãã§ãã
ïŒäŸãã°ãç±³åœç¹èš±ç¬¬3669841å·åç §ïŒãé©ããŠã
ãã°ãäžæŽ»æ§æ äœäžã«ã¬ã»ãã¿ãäžååããã«é
ããŠãåçŽãªåžçã«ãããŠèµ·ãããããªãã€ãªã³
çµåãçæ°Žçžäºäœçšããã¢ã³ãã«ã¯ãŒã«ã¹ã«çã
å©çšããŠãããã
ããæè¡ã¯ãæ¬æ现æžã§è©³è¿°ããå¿ èŠããªãçšæ¢
ã«é²æ©ããŠãããåçš®ã®äžæŽ»æ§ç²åãããŒãºãè¡š
é¢ïŒäŸãã°ãåæïŒææ©ïŒããªããŒãã»ã©ãã
ã¯ãç¡æ©ç²æ«ã倩ç¶ããªããŒãã»ã«ããŒã¹ãã¢ã¬
ããŒã¹çïŒã䜿çšããåŸããã奜ãŸããåºäœã¯ã¬
ã©ã¹ã§ãããäŸãã°ãç±³åœããµããŠãŒã»ããå·ã¡
ããã€ã«ãã®Corning Medical and Scientific
瀟ããå ¥æã§ãå€ãã®IMMOPHASEåææ³ã§
çšããããŠãããããªã¬ã©ã¹ç²åã§ãããããã
ã®ã¬ã©ã¹ã¯ãå€ãã®å Žåãã¢ããã·ã©ã³ã«ãã€ãŠ
åŠçããããã®å€å床ã調æŽãåŸããã®ã§ããã
ã¬ã»ãã¿ã¯ãå ±æçµåãä»ããŠåºäœã«çµåããã
ã®ãéåžžã§ããããã®éãåœè©²æè¡åéã«ãããŠ
ããç¥ãããŠããããã«ãååšããåå¿åºã«å¿ã
ãŠã¹ããŒãµéšåãçšãããããçšããããªãã€ã
ããããäŸãã°ãåœè©²æè¡åéã«ãããŠè¯ãç¥ã
ããŠããããã«ã¢ããã·ã©ã³çµåããã³ã°ã«ã¿ãŒ
ã«ã¢ã«ããããä»ããŠãå€å床ã調æŽãããã¬ã©
ã¹ç²åã«å å æ§å åãåå¿ãããããšãã§ãã
ïŒäŸãã°ãç±³åœç¹èš±ç¬¬3669841å·åç §ïŒãé©ããŠã
ãã°ãäžæŽ»æ§æ äœäžã«ã¬ã»ãã¿ãäžååããã«é
ããŠãåçŽãªåžçã«ãããŠèµ·ãããããªãã€ãªã³
çµåãçæ°Žçžäºäœçšããã¢ã³ãã«ã¯ãŒã«ã¹ã«çã
å©çšããŠãããã
ã¬ã»ãã¿ã¯ãçç©çµç¹ã«èŠåºããããã®ãšæ¬è³ª
çã«åããã®ã§ãããããŸãã¯å€©ç¶ã«ååšããã¬
ã»ãã¿ã«æš¡åãããããªãã®ãéžã¶ã¹ãã§ããã
æã«ã¯ãæœåºãå®å®ååŠçãªã©ã«éããŠå€æ§ãç
ããããåæã«å¿ èŠãªçµåãµã€ããå€ãããªãé
ãã¯èš±å®¹ã§ãããå¿è«ãå€ãã®å Žåãã¬ã»ãã¿
ã¯ã人éããåŸããããã®ã®ä»£ããã«ãäœçŽåç©
ããåŸãããé¡äŒŒç©è³ªã§ãããæŽã«ãä»ã®å€©ç¶ã«
ååšããç©è³ªãå©çšããããšãã§ãããŸããå¿ èŠ
ãªéšåã®çµåãµã€ãã倩ç¶ã«ååšããã¬ã»ãã¿ã®
çµåãµã€ããšåãã§ããéãã«ãããŠã¯ãåæç©
質ãçšããããšãã§ããããããã€ãŠãäºæ³ãã
ãèªå·±é®ææäœãçµåããããšãã§ãããããªé
èçœè³ªç³»ã®ç©è³ªãäŸãã°ãã€ãªã³äº€ææš¹èãçæ°Ž
æ§ç©è³ªçãã¬ã»ãã¿ãšããããšããããæã«ã¯ã
ã¬ã»ãã¿ãèçœè³ªã§ãããªãããçµåã¯èçœè³ªã®
éèçœè³ªéšåïŒäŸãã°ãçæ°Žåç©ãè質ããã³
ïŒãŸãã¯ïŒããããéšåïŒãä»ããŠçããããšã
ããããŸããçäœå€ã®å®éšã«ããã°ãã¬ã©ã¹ç²å
ã«ã¯ãèçœè³ªãããªãèçœè³ªè¡šé¢ã«æš¡åãããã®
ãåããããšã瀺ãããŠããã
çã«åããã®ã§ãããããŸãã¯å€©ç¶ã«ååšããã¬
ã»ãã¿ã«æš¡åãããããªãã®ãéžã¶ã¹ãã§ããã
æã«ã¯ãæœåºãå®å®ååŠçãªã©ã«éããŠå€æ§ãç
ããããåæã«å¿ èŠãªçµåãµã€ããå€ãããªãé
ãã¯èš±å®¹ã§ãããå¿è«ãå€ãã®å Žåãã¬ã»ãã¿
ã¯ã人éããåŸããããã®ã®ä»£ããã«ãäœçŽåç©
ããåŸãããé¡äŒŒç©è³ªã§ãããæŽã«ãä»ã®å€©ç¶ã«
ååšããç©è³ªãå©çšããããšãã§ãããŸããå¿ èŠ
ãªéšåã®çµåãµã€ãã倩ç¶ã«ååšããã¬ã»ãã¿ã®
çµåãµã€ããšåãã§ããéãã«ãããŠã¯ãåæç©
質ãçšããããšãã§ããããããã€ãŠãäºæ³ãã
ãèªå·±é®ææäœãçµåããããšãã§ãããããªé
èçœè³ªç³»ã®ç©è³ªãäŸãã°ãã€ãªã³äº€ææš¹èãçæ°Ž
æ§ç©è³ªçãã¬ã»ãã¿ãšããããšããããæã«ã¯ã
ã¬ã»ãã¿ãèçœè³ªã§ãããªãããçµåã¯èçœè³ªã®
éèçœè³ªéšåïŒäŸãã°ãçæ°Žåç©ãè質ããã³
ïŒãŸãã¯ïŒããããéšåïŒãä»ããŠçããããšã
ããããŸããçäœå€ã®å®éšã«ããã°ãã¬ã©ã¹ç²å
ã«ã¯ãèçœè³ªãããªãèçœè³ªè¡šé¢ã«æš¡åãããã®
ãåããããšã瀺ãããŠããã
æ¬çºæã«ãããŠæ¬¡ã«éèŠãªè©Šè¬ã¯ãæšèä»ãã
ãããªã¬ã³ãã§ãããã¬ã»ãã¿ã®å Žåãšåæ§ã«ã
ãªã¬ã³ãã¯ãçäœçµç¹ã«åãããã®ã奜ãŸãã
ããçäœçµç¹ã«åãããã®ãå€æ§ããããã®ã§ã
ãããæŽã«ã¯ãçµåãµã€ããã¬ã»ãã¿ãšéžæçã«
çµåããã®ã«å¿ èŠãšããããããªãã®ã§ããéã
ã¯ãçäœçµç¹å ã«ãããŠã¯æ©èœããªããããªåæ
ç©è³ªã§ãã€ãŠãããã
ãããªã¬ã³ãã§ãããã¬ã»ãã¿ã®å Žåãšåæ§ã«ã
ãªã¬ã³ãã¯ãçäœçµç¹ã«åãããã®ã奜ãŸãã
ããçäœçµç¹ã«åãããã®ãå€æ§ããããã®ã§ã
ãããæŽã«ã¯ãçµåãµã€ããã¬ã»ãã¿ãšéžæçã«
çµåããã®ã«å¿ èŠãšããããããªãã®ã§ããéã
ã¯ãçäœçµç¹å ã«ãããŠã¯æ©èœããªããããªåæ
ç©è³ªã§ãã€ãŠãããã
ãã¹ãã«çšããããæ£è
ã®è©Šæã¯ãæäœãååš
ãããšèããããçäœæ¶²ã§ãããè¡æž ãè¡æŒ¿ãçš
ããããã®ãéåžžã§ããããè©Šè¬ãæäœã«å¿ã
ãŠãèæ±æ¶²ãå°¿ãè液ãè¡æ¶²çã®ä»ã®æµäœãçšã
ãããšãã§ããã
ãããšèããããçäœæ¶²ã§ãããè¡æž ãè¡æŒ¿ãçš
ããããã®ãéåžžã§ããããè©Šè¬ãæäœã«å¿ã
ãŠãèæ±æ¶²ãå°¿ãè液ãè¡æ¶²çã®ä»ã®æµäœãçšã
ãããšãã§ããã
æ¬çºæã¯ããŸããäžååãããã¬ã»ãã¿ãšæšè
ä»ãããããªã¬ã³ããå«æããè©Šè¬ãããã«ãä¿
ãã該詊è¬ãããã¯ãæ£è ã®çäœæ¶²ãäžååãã
ãã¬ã»ãã¿ã«æ··åãã次ãã§ãæšèä»ããªã¬ã³ã
ãæ·»å ããããšãããªãæ¹æ³ã«çšãããããäžå
åã¬ã»ãã¿ãšçµåããæšèä»ãããããªã¬ã³ãã®
çžå¯Ÿéãæ±ããããšã«ãããåé¡ãšãªãç¹å®ã®èª
å·±é®ææäœã®ååšãå®æ§çãŸãã¯å®éçã«è©äŸ¡ã
ãã
ä»ãããããªã¬ã³ããå«æããè©Šè¬ãããã«ãä¿
ãã該詊è¬ãããã¯ãæ£è ã®çäœæ¶²ãäžååãã
ãã¬ã»ãã¿ã«æ··åãã次ãã§ãæšèä»ããªã¬ã³ã
ãæ·»å ããããšãããªãæ¹æ³ã«çšãããããäžå
åã¬ã»ãã¿ãšçµåããæšèä»ãããããªã¬ã³ãã®
çžå¯Ÿéãæ±ããããšã«ãããåé¡ãšãªãç¹å®ã®èª
å·±é®ææäœã®ååšãå®æ§çãŸãã¯å®éçã«è©äŸ¡ã
ãã
ãªã¬ã³ãã¯ãæŸå°æ§ã©ãã«ãé
µçŽ ã©ãã«ãèå
æ§ã©ãã«çãçšããããšã«ããä»»æã®æ¹æ³ã«åŸã€
ãŠæšèä»ããããããšãã§ããã
æ§ã©ãã«çãçšããããšã«ããä»»æã®æ¹æ³ã«åŸã€
ãŠæšèä»ããããããšãã§ããã
奜ãŸããã¯ãå°ãªããšããåé¡ãšãªãç¹å®ã®èª
å·±é®ææäœãå šãå«æããŠããªãããšãããã€ãŠ
ããé°æ§ã®æ€éäœãè©Šè¬ãããã«å«ãŸããŠããã
ããããªãããé°æ§æ€éäœããã³éœæ§æ€éäœã®å
æ¹ãå«ãŸããŠãæ£è ã®è©Šæãšå ±ã«åŠçããããšã
äžå±€å¥œãŸãããéœæ§æ€éäœãšã¯ããã¹ãã®æ床ã«
å¿ããŠéœæ§åå¿ãäžãå§ããããã«äºãå®ããã
ãéã®èªå·±é®ææäœãå«æããè©Šè¬ã§ãããããª
ãã¡ãããè©Šæãéœæ§æ€éäœã®ãéœæ§ãåŽã«åã
ããšãã¯ã該詊æã«èªå·±é®ææäœãååšããããš
ããéœæ§ïŒè²¢å®çïŒãã§ããããŸããããè©Šæã
ãéœæ§ãæ€éäœãšãé°æ§ãæ€éäœãšã®äžéã«åã
ããšãã¯ãç°è²ãïŒããªãã¡ãæäœãååšããã
ãšãæ確ã§ãªãïŒé åã«åããããšã«ãªãâåŸè
ã®å Žåããã¹ãã®æ床ã«å¿ããŠéœæ§ã«ãªã€ããé°
æ§ã«ãªã€ããããã§ããããææãªãã°ã匷ãéœ
æ§ã®å¯Ÿç §äœã«ã€ããŠãæäœãè¡ãªãã匷ãéœæ§çµ
æã瀺ãïŒæäœã®ååšã確å®ã«ç¥ãïŒãä»ã®è©Šè¬
ã«å¯Ÿããããã«ããšãã¯ãè¡ãªã€ãŠããããæŽ
ã«ããªã¬ã³ãã«çšããã©ãã«ïŒæšèïŒã®çš®é¡ã«å¿
ããŠïŒç¹ã«æŸå°æ§ãªã¬ã³ããçšããå Žåã«ã¯ïŒã
ããã¯ã°ã©ã³ãã®å¯Ÿç §æäœãè¡ãªãããšãã§ã
ãã
å·±é®ææäœãå šãå«æããŠããªãããšãããã€ãŠ
ããé°æ§ã®æ€éäœãè©Šè¬ãããã«å«ãŸããŠããã
ããããªãããé°æ§æ€éäœããã³éœæ§æ€éäœã®å
æ¹ãå«ãŸããŠãæ£è ã®è©Šæãšå ±ã«åŠçããããšã
äžå±€å¥œãŸãããéœæ§æ€éäœãšã¯ããã¹ãã®æ床ã«
å¿ããŠéœæ§åå¿ãäžãå§ããããã«äºãå®ããã
ãéã®èªå·±é®ææäœãå«æããè©Šè¬ã§ãããããª
ãã¡ãããè©Šæãéœæ§æ€éäœã®ãéœæ§ãåŽã«åã
ããšãã¯ã該詊æã«èªå·±é®ææäœãååšããããš
ããéœæ§ïŒè²¢å®çïŒãã§ããããŸããããè©Šæã
ãéœæ§ãæ€éäœãšãé°æ§ãæ€éäœãšã®äžéã«åã
ããšãã¯ãç°è²ãïŒããªãã¡ãæäœãååšããã
ãšãæ確ã§ãªãïŒé åã«åããããšã«ãªãâåŸè
ã®å Žåããã¹ãã®æ床ã«å¿ããŠéœæ§ã«ãªã€ããé°
æ§ã«ãªã€ããããã§ããããææãªãã°ã匷ãéœ
æ§ã®å¯Ÿç §äœã«ã€ããŠãæäœãè¡ãªãã匷ãéœæ§çµ
æã瀺ãïŒæäœã®ååšã確å®ã«ç¥ãïŒãä»ã®è©Šè¬
ã«å¯Ÿããããã«ããšãã¯ãè¡ãªã€ãŠããããæŽ
ã«ããªã¬ã³ãã«çšããã©ãã«ïŒæšèïŒã®çš®é¡ã«å¿
ããŠïŒç¹ã«æŸå°æ§ãªã¬ã³ããçšããå Žåã«ã¯ïŒã
ããã¯ã°ã©ã³ãã®å¯Ÿç §æäœãè¡ãªãããšãã§ã
ãã
å®æœäŸ
次ã®ïŒæåãæããè©Šè¬ããããçšããŠãIF
é®æãµã€ãæäœã®ã©ãžãªã¢ãã»ã€ãè¡ãªãã
é®æãµã€ãæäœã®ã©ãžãªã¢ãã»ã€ãè¡ãªãã
 å
å æ§å åïŒäžååã¬ã»ãã¿èçœè³ªïŒ
å
å æ§å åïŒç²Ÿè£œããè±ã®å
å æ§å åïŒãã¬
ã©ã¹ç²åã«å ±æçµåããããã®ããä¿åå€ãšã
ãŠ0.2ïŒ ã®ã¢ãžåãããªãŠã ãå«æãã0.03M
ã®ãªã³é žå¡©ç³»ç·©è¡æ¶²ïŒ0.15MãPH7.4ïŒã«æžæ¿
ããããã®ã
ã©ã¹ç²åã«å ±æçµåããããã®ããä¿åå€ãšã
ãŠ0.2ïŒ ã®ã¢ãžåãããªãŠã ãå«æãã0.03M
ã®ãªã³é žå¡©ç³»ç·©è¡æ¶²ïŒ0.15MãPH7.4ïŒã«æžæ¿
ããããã®ã
 ã 57Coããã¿ãã³B12ïŒæŸå°æ§ãªã¬ã³ãïŒ
ã 57Coããã¿ãã³B12ãã0.001ïŒ
ã·ã¢ã³å
ã«ãªãŠã ãããããå©å€ãšããŠã¢ãã©ã³ã¹èµ€è²
ææïŒïŒÎŒïœ/mlïŒãããã³ãä¿åå€ãšããŠ0.2ïŒ
ã®ã¢ãžåãããªãŠã ãå«æãã0.1Mã®ããŠé ž
å¡©ç·©è¡æ¶²ïŒPH9.3ïŒã«æº¶è§£ããããã®ã
ã«ãªãŠã ãããããå©å€ãšããŠã¢ãã©ã³ã¹èµ€è²
ææïŒïŒÎŒïœ/mlïŒãããã³ãä¿åå€ãšããŠ0.2ïŒ
ã®ã¢ãžåãããªãŠã ãå«æãã0.1Mã®ããŠé ž
å¡©ç·©è¡æ¶²ïŒPH9.3ïŒã«æº¶è§£ããããã®ã
 ãžããªã¹ã¬ã€ããŒã«ïŒééžææ§çµåãåäžã
ããããã®ä»»ææåïŒ åæã«é©ãããããªæ¿åºŠã«èª¿æŽãã1.0mlã®
ãžããªã¹ã¬ã€ããŒã«ãå«æãããã€ã¢ã«ã
ããããã®ä»»ææåïŒ åæã«é©ãããããªæ¿åºŠã«èª¿æŽãã1.0mlã®
ãžããªã¹ã¬ã€ããŒã«ãå«æãããã€ã¢ã«ã
 é°æ§æ€éäœ
ç¹ç¶çŽ é€å»ãã人éã®è¡æŒ¿ããæãããã®ç©è³ª
ã¯ãåçµä¹Ÿç¥ãã䜿çšããéã«å調補ããåŸãã
ãã«ãªã€ãŠããã
ã¯ãåçµä¹Ÿç¥ãã䜿çšããéã«å調補ããåŸãã
ãã«ãªã€ãŠããã
 éœæ§æ€éäœ
å
å æ§å åã«å¯Ÿããé®ææäœãå«æããçšè
ãªäººéã®è¡æŒ¿ããæäœé°æ§ãšæäœéœæ§ã®å¢çç¹
ïŒcutoff pointïŒãå®ããæ¿åºŠã«ãããã®ã該
è¡æŒ¿ã®çšè液ã¯ãå å æ§å åã«å¯Ÿããé®ææäœ
ãå«æããªãç¹ç¶çŽ é€å»ãã人éã®è¡æŒ¿ããå
é¢ãããã®ã§ããããã®ç©è³ªã¯ãåçµä¹Ÿç¥ãã
ãããšãã§ããŠã䜿çšã«éããŠå調補ããåŸ
ããæã¡åãç¹ã¯ãæäœãæããªãæ£åžžãªè©Šæ
çŽ800ãšãé®ææäœãæããè©ŠæçŽ100ãšãè©äŸ¡
ããããšã«ãã€ãŠæ±ãããããæ£åžžãªè©Šæã®å¹³
åããã®æšæºåå·®ãïŒãšãªãç¹ã«ãããå¿çã
æã¡åãç¹ãšãããéœæ§è©Šæã¯ãã®å¢çã«ã¯å«
ãŸããªãã
ãªäººéã®è¡æŒ¿ããæäœé°æ§ãšæäœéœæ§ã®å¢çç¹
ïŒcutoff pointïŒãå®ããæ¿åºŠã«ãããã®ã該
è¡æŒ¿ã®çšè液ã¯ãå å æ§å åã«å¯Ÿããé®ææäœ
ãå«æããªãç¹ç¶çŽ é€å»ãã人éã®è¡æŒ¿ããå
é¢ãããã®ã§ããããã®ç©è³ªã¯ãåçµä¹Ÿç¥ãã
ãããšãã§ããŠã䜿çšã«éããŠå調補ããåŸ
ããæã¡åãç¹ã¯ãæäœãæããªãæ£åžžãªè©Šæ
çŽ800ãšãé®ææäœãæããè©ŠæçŽ100ãšãè©äŸ¡
ããããšã«ãã€ãŠæ±ãããããæ£åžžãªè©Šæã®å¹³
åããã®æšæºåå·®ãïŒãšãªãç¹ã«ãããå¿çã
æã¡åãç¹ãšãããéœæ§è©Šæã¯ãã®å¢çã«ã¯å«
ãŸããªãã
 éœæ§å¯Ÿç
§äœ
ãã®éœæ§å¯Ÿç
§äœã¯ãéœæ§æ€éäœãšåãç©è³ªã
ã補ããããã®ã§ãããäœããæ·»å ããé®ææ
äœã®éãå€ãããŠãåæã«éããŠéœæ§å¿çã®æ
床ãé«ããã
ã補ããããã®ã§ãããäœããæ·»å ããé®ææ
äœã®éãå€ãããŠãåæã«éããŠéœæ§å¿çã®æ
床ãé«ããã
äžè¿°ã®åè©Šè¬ã貯èµãå調補ãŸãã¯åæ±ããã
ã«ãåœæ¥è ã«ãšã€ãŠæ¢ç¥ã®åçš®ã®ææ³ãçšããã
ãããããã®è©Šè¬ã¯ã䜿çšæã«ã¯å®€æž©äžã«ããã
ã«ãåœæ¥è ã«ãšã€ãŠæ¢ç¥ã®åçš®ã®ææ³ãçšããã
ãããããã®è©Šè¬ã¯ã䜿çšæã«ã¯å®€æž©äžã«ããã
æ€å®æ³ïŒåææ³ïŒ
æ©æ¢°ã®ããã¯ã°ã©ã³ããé°æ§æ€éäœïŒ100ÎŒïŒ
ããã³éœæ§æ€éäœïŒ100ÎŒïŒã«ã€ããŠã¯ïŒåã®
æäœãè¡ãªããä»ã®è©ŠæïŒåã100ÎŒïŒã«ã€ã
ãŠã¯ïŒåã®æäœãè¡ãªãããšã奜ãŸãããããã
ãŠãããããã®è©Šæã®å¹³åå€ãçšããŠä»¥äžã«èšã
ãããªèšç®ãè¡ãªãã
ããã³éœæ§æ€éäœïŒ100ÎŒïŒã«ã€ããŠã¯ïŒåã®
æäœãè¡ãªããä»ã®è©ŠæïŒåã100ÎŒïŒã«ã€ã
ãŠã¯ïŒåã®æäœãè¡ãªãããšã奜ãŸãããããã
ãŠãããããã®è©Šæã®å¹³åå€ãçšããŠä»¥äžã«èšã
ãããªèšç®ãè¡ãªãã
äžè¿°ã®å¥œãŸããæ
æ§ãèæ
®ããŠã次ã®ãããªã
ã¹ãã®æºåãè¡ãªãã
ã¹ãã®æºåãè¡ãªãã
è©Šéšç®¡ã®çªå· 管ã®å
容ç©
ïŒãïŒ ç©ºïŒããã¯ã°ã©ã³ãã®ãã€ãºçšïŒ
ïŒãïŒ é°æ§æ€éäœ
ïŒã12 éœæ§æ€éäœ
13ã14 éœæ§å¯Ÿç
§äœ
15ã16 æ£è
ã®è¡æž
è©Šæ
ããªãã¡ãåæãå§ããã«åœã€ãŠãå100ÎŒ
ã®è©Šè¬ïŒ€ãå«æãã管ïŒãïŒãå100ÎŒã®è©Šè¬
ãå«æãã管ïŒã12ãå100ÎŒã®è©Šè¬ïŒŠãå«
æãã管13ã14ãããã³ãå100ÎŒã®çäœæ¶²è©Š
æãå«æãã管15ã16ãçšæããã
ã®è©Šè¬ïŒ€ãå«æãã管ïŒãïŒãå100ÎŒã®è©Šè¬
ãå«æãã管ïŒã12ãå100ÎŒã®è©Šè¬ïŒŠãå«
æãã管13ã14ãããã³ãå100ÎŒã®çäœæ¶²è©Š
æãå«æãã管15ã16ãçšæããã
次ã«ãæ¢ç¥éïŒ0.5mlïŒã®äžååããå
å æ§å
åïŒè©Šè¬ïŒ¡ïŒãã管ïŒã16ã«æ·»å ãããå管ãæ¹
æãããããåŸãå å æ§å åãšæäœãšã®éã§è€å
äœã圢æãã枩床ã«ãããŠå¹é€ïŒäŸãã°ã宀枩äž
ã§çŽïŒæéïŒããã次ãã§ãå管ãé å¿åé¢ãã
ã«ã³ããããè¡æž äžã«ååšããå å æ§ãã¿ãã³
B12çµåæ§èçœè³ªã¯ããã®å·¥çšã«ãããŠãã«ã³ã
ãŒã·ãšã³ã«ããé€å»ãããããšã«ãªããæ¢ç¥é
ïŒ1.0mlïŒã®æŸå°æ§ãªã¬ã³ãïŒè©Šè¬ïŒ¢ïŒã管ïŒã16
ã«æ·»å ããæŽã«å¹é€ïŒäŸãã°ã宀枩äžã«ãããŠçŽ
ïŒæéïŒã«äŸãããåã³é å¿åé¢ãè¡ãªãã次ã
ã§ãã«ã³ããŒã·ãšã³ãè¡ãªããå管ã®æŸå°èœã枬
å®ããã
åïŒè©Šè¬ïŒ¡ïŒãã管ïŒã16ã«æ·»å ãããå管ãæ¹
æãããããåŸãå å æ§å åãšæäœãšã®éã§è€å
äœã圢æãã枩床ã«ãããŠå¹é€ïŒäŸãã°ã宀枩äž
ã§çŽïŒæéïŒããã次ãã§ãå管ãé å¿åé¢ãã
ã«ã³ããããè¡æž äžã«ååšããå å æ§ãã¿ãã³
B12çµåæ§èçœè³ªã¯ããã®å·¥çšã«ãããŠãã«ã³ã
ãŒã·ãšã³ã«ããé€å»ãããããšã«ãªããæ¢ç¥é
ïŒ1.0mlïŒã®æŸå°æ§ãªã¬ã³ãïŒè©Šè¬ïŒ¢ïŒã管ïŒã16
ã«æ·»å ããæŽã«å¹é€ïŒäŸãã°ã宀枩äžã«ãããŠçŽ
ïŒæéïŒã«äŸãããåã³é å¿åé¢ãè¡ãªãã次ã
ã§ãã«ã³ããŒã·ãšã³ãè¡ãªããå管ã®æŸå°èœã枬
å®ããã
ãããæ£è
ã«ãã¿ãã³B12ãæäžãããŠãã
ã°ãåæäžã«æ£è ã®è©ŠæãåŠçããŠïŒäŸãã°è©Šè¬
ã«ãã¿ãã³B12çµåå€ãäºãæ··åããŠããïŒå
åšããéé¢ã®ãã¿ãã³B12ãé€å»ããããšãã§ã
ãã代ããã«ãäžååãããå å æ§å åãæ·»å ã
ãåã«ã管15ã16ã«ãã¿ãã³B12ãæ·»å ããŠãã
ããäžè¬çã«èšãã°ã2000pïœ/mlãŸã§ã®ãã¿ã
ã³B12ãå«ãè¡æž è©Šæã§ããã°ãåæã劚害ãã
çšåºŠã®éé¢ãã¿ãã³B12ãå«æããŠã¯ããªãã
ã°ãåæäžã«æ£è ã®è©ŠæãåŠçããŠïŒäŸãã°è©Šè¬
ã«ãã¿ãã³B12çµåå€ãäºãæ··åããŠããïŒå
åšããéé¢ã®ãã¿ãã³B12ãé€å»ããããšãã§ã
ãã代ããã«ãäžååãããå å æ§å åãæ·»å ã
ãåã«ã管15ã16ã«ãã¿ãã³B12ãæ·»å ããŠãã
ããäžè¬çã«èšãã°ã2000pïœ/mlãŸã§ã®ãã¿ã
ã³B12ãå«ãè¡æž è©Šæã§ããã°ãåæã劚害ãã
çšåºŠã®éé¢ãã¿ãã³B12ãå«æããŠã¯ããªãã
ãžããªã¹ã¬ã€ããŒã«ãçšããå Žåã«ã¯ãæŸå°æ§
ãã¿ãã³B12溶液ã®ïŒæåãšããŠæŸå°æ§ãªã¬ã³ã
ãæ·»å ããéã«è©Šæã«è©²ãžããªã¹ã¬ã€ããŒã«ãæ·»
å ããããã®æåã®äœ¿çšã¯ãééžæçãªçµåãå
äžãããããã®ä»»æçãªãã®ã§ããã
ãã¿ãã³B12溶液ã®ïŒæåãšããŠæŸå°æ§ãªã¬ã³ã
ãæ·»å ããéã«è©Šæã«è©²ãžããªã¹ã¬ã€ããŒã«ãæ·»
å ããããã®æåã®äœ¿çšã¯ãééžæçãªçµåãå
äžãããããã®ä»»æçãªãã®ã§ããã
è©Šæã®èšç®æ³
çšããæ°å€ã¯å
šãŠãå¹³åå€ããããã¯ã°ã©ã³ã
çšã®ç®¡ã®å¹³åã®ã«ãŠã³ãæ°ãæžãããã®ã§ããã
ãã®ãã¹ãæ³ã¯å®æ§çãªãã®ã§ããããèšç®ã¯ç°¡
åã§ãããé°æ§æ€éäœããåŸãããïŒååœãã®æ£
å³ã®ã«ãŠã³ãæ°ãéœæ§æ€éäœããåŸãããïŒååœ
ãã®æ£å³ã®ã«ãŠã³ãæ°ã§é€ãããšã1.00ããã倧
ããªå€(A)ãåŸãããã次ãã§ãæªç¥è©Šæã®åã ã
ãåŸãããæ£å³ã®ã«ãŠã³ãæ°ããé°æ§æ€éäœã®å€
ã§é€ããããšã«ãã€ãŠãåæªç¥è©Šæã«ã€ããŠã®æ°
å€ãåŸããããçµéšäžãåæãæå¹ã§ããããã«
ã¯ã(A)ã¯1.15ã1.15ããã倧ãããªããã°ãªããª
ããããããŠãæªç¥è©Šæã«ã€ããŠã®äžèšã®å€ã(A)
ãããå°ããã(A)ã«çãããªãã°ã該æªç¥è©Šæã¯
æäœã«é¢ããŠé°æ§ã§ãããšæšå®ããããä»æ¹ãæª
ç¥è©Šæã«ã€ããŠã®å€ã(A)ããã倧ãããªãã°ã該
æªç¥è©Šæã¯æäœã«é¢ããŠéœæ§ã§ãããå¿è«ã(A)ãš
1.00ãšã®éã«ã¯ãç°è²ïŒäžç¢ºå®ïŒãé åãåããã
çšã®ç®¡ã®å¹³åã®ã«ãŠã³ãæ°ãæžãããã®ã§ããã
ãã®ãã¹ãæ³ã¯å®æ§çãªãã®ã§ããããèšç®ã¯ç°¡
åã§ãããé°æ§æ€éäœããåŸãããïŒååœãã®æ£
å³ã®ã«ãŠã³ãæ°ãéœæ§æ€éäœããåŸãããïŒååœ
ãã®æ£å³ã®ã«ãŠã³ãæ°ã§é€ãããšã1.00ããã倧
ããªå€(A)ãåŸãããã次ãã§ãæªç¥è©Šæã®åã ã
ãåŸãããæ£å³ã®ã«ãŠã³ãæ°ããé°æ§æ€éäœã®å€
ã§é€ããããšã«ãã€ãŠãåæªç¥è©Šæã«ã€ããŠã®æ°
å€ãåŸããããçµéšäžãåæãæå¹ã§ããããã«
ã¯ã(A)ã¯1.15ã1.15ããã倧ãããªããã°ãªããª
ããããããŠãæªç¥è©Šæã«ã€ããŠã®äžèšã®å€ã(A)
ãããå°ããã(A)ã«çãããªãã°ã該æªç¥è©Šæã¯
æäœã«é¢ããŠé°æ§ã§ãããšæšå®ããããä»æ¹ãæª
ç¥è©Šæã«ã€ããŠã®å€ã(A)ããã倧ãããªãã°ã該
æªç¥è©Šæã¯æäœã«é¢ããŠéœæ§ã§ãããå¿è«ã(A)ãš
1.00ãšã®éã«ã¯ãç°è²ïŒäžç¢ºå®ïŒãé åãåããã
åœæ¥è
ã«ãšã€ãŠã¯ãäžè¿°ã®æ¬çºæãå€æŽããã
ãšã¯æããã§ããããäŸãã°ãå¹é€ã®æ¡ä»¶ã¯åºç¯
å²ã«å€æŽãåŸããã®ã§ãããææã«å¿ããŠæŽæ»å·¥
çšãçšããããšãã§ãããŸããåé¢æäœã¯é å¿å
é¢ãšãã«ã³ããŒã·ãšã³ã«éããããäžè¿°ãšç°ãªã
ææ³ã§èšç®ãè¡ãªãããšãã§ããæŽã«ãäžååæ
äœã«çµåããªãã€ããªã¬ã³ãã«ã€ããŠåŸãããå€
ãçšããŠé°æ§ããã³éœæ§ã®å¿çãèšç®ããããšã
ã§ããã
ãšã¯æããã§ããããäŸãã°ãå¹é€ã®æ¡ä»¶ã¯åºç¯
å²ã«å€æŽãåŸããã®ã§ãããææã«å¿ããŠæŽæ»å·¥
çšãçšããããšãã§ãããŸããåé¢æäœã¯é å¿å
é¢ãšãã«ã³ããŒã·ãšã³ã«éããããäžè¿°ãšç°ãªã
ææ³ã§èšç®ãè¡ãªãããšãã§ããæŽã«ãäžååæ
äœã«çµåããªãã€ããªã¬ã³ãã«ã€ããŠåŸãããå€
ãçšããŠé°æ§ããã³éœæ§ã®å¿çãèšç®ããããšã
ã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ èªå·±é®ææäœã®ååšãæ€ç¥ããæ¹æ³ã§ãã€
ãŠã (a) èªå·±é®ææäœãå«æããŠãããšèããããç
äœæ¶²è©Šæãã該æäœã«å¯Ÿããéžæçãªçµåãµã€
ããæããã€äžæŽ»æ§æ äœäžã«äžååãããã¬ã»
ãã¿ãšæ··åãïŒ (b) åèšã®å·¥çš(a)ã«ããåŸãæ··åç©ããååšãã
åèšé®ææäœã®å®è³ªçã«ãã¹ãŠãåèšã¬ã»ãã¿
ã«çµåããããšãã§ããã®ã«å åãªæ¡ä»¶äžã«å¹
é€ããããšã«ãããé®ææäœãçµåããåèšäž
掻æ§æ äœãããªãåºäœçžãšãåèšé®ææäœãæ
ããªãåèšçäœæ¶²è©Šæãããªã液äœçžãšãåŸïŒ (c) åèšæ¶²äœçžããåèšåºäœçžãåé¢ãïŒ (d) åèšéžæççµåãµã€ãã«çµåããæšèä»ãã
ãããªã¬ã³ããããªã液äœçžããåèšåé¢ãã
ãåºäœçžãšæ··åãïŒ (e) åèšå·¥çš(d)ã«ããåŸãæ··åç©ããåèšã¬ã»ã
ã¿ã®éžæççµåãµã€ãã®ãã¡åèšé®ææäœãšçµ
åããŠããªããµã€ãã«åèšæšèä»ãªã¬ã³ããçµ
åãåŸãã«å åãªæ¡ä»¶äžã«å¹é€ããããšã«ã
ããé®ææäœããã³æšèä»ãªã¬ã³ãã®å°ãªããš
ãäžæ¹ãçµåããåèšäžæŽ»æ§æ äœãããªã第ïŒ
ã®åºäœçžãšãæªçµåã®æšèä»ãªã¬ã³ããããªã
第ïŒã®æ¶²äœçžãšãåŸïŒ (f) åèšç¬¬ïŒã®æ¶²äœçžããåèšç¬¬ïŒã®åºäœçžãå
é¢ãïŒããã« (g) åèšç¬¬ïŒã®åºäœçžããã³åèšç¬¬ïŒã®æ¶²äœçžã®
å°ãªããšãäžæ¹ã«ååšããæšèä»ãªã¬ã³ãã®é
ã枬å®ããããšã ãããªãããšãç¹åŸŽãšããåèšæ¹æ³ã ïŒ ã¬ã»ãã¿ãèçœè³ªã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®æ¹æ³ã ïŒ å¯Ÿç §çšã«ãæ¢ç¥ã®é°æ§æ€éäœããã³æ¢ç¥ã®éœ
æ§æ€éäœã«ã€ããŠæäœãè¡ãªãããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ ã¬ã»ãã¿ãå å æ§å åã§ããããªã¬ã³ããã
ã¿ãã³B12ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãŸãã¯ç¬¬
ïŒé èšèŒã®æ¹æ³ã ïŒ ã¬ã»ãã¿ãå å æ§å åã§ããããªã¬ã³ããã
ã¿ãã³B12ã§ãããé°æ§æ€éäœã人éã®è¡æŒ¿ãã
調補ããããŸããéœæ§æ€éäœãåèšèªå·±é®ææäœ
ãå«æãã人éã®è¡æŒ¿ãã調補ãããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ äžæŽ»æ§æ äœãã¬ã©ã¹ç²åã§ããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé ã第ïŒé ã®ããããïŒé ã«èšèŒã®æ¹æ³ã ïŒ ã¬ã»ãã¿ããåèšã¬ã©ã¹ã«å ±æçµåããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ æšèä»ãããæŸå°æ§ç©è³ªãèå æ§ç©è³ªãŸãã¯
é µçŽ ãä»ããŠè¡ãªãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã
第ïŒé ã®ããããïŒé ã«èšèŒã®æ¹æ³ã ïŒ èªå·±èšºææäœã®ååšãæ€ç¥ããã®ã«çšããã
ãè©Šè¬ãããã§ãã€ãŠãåèšæäœã«å¯Ÿããéžæç
çµåãµã€ããæããã€äžæŽ»æ§æ äœäžã«äžååãã
ãã¬ã»ãã¿ãšã該éžæççµåãµã€ãã«çµåããæš
èä»ãããããªã¬ã³ããšãããªãåèšè©Šè¬ãã
ãã ïŒïŒ ã¬ã»ãã¿ãèçœè³ªãŸãã¯å å æ§å åã§ã
ãããªã¬ã³ãããã¿ãã³B12ã§ããã人éã®è¡æŒ¿
ãã調補ãããé°æ§æ€éäœãšãèªå·±é®ææäœãå«
æãã人éã®è¡æŒ¿ãã調補ãããéœæ§æ€éäœãå«
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®è©Šè¬ãããã ïŒïŒ åèšéœæ§æ€éäœãããå€éã®åèšèªå·±é®æ
æäœãå«æãã人éã®è¡æŒ¿ãã調補ãããéœæ§å¯Ÿ
ç §äœãå«ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è©Šè¬ã
ããã ïŒïŒ äžæŽ»æ§æ äœãã¬ã©ã¹ç²åã§ãããã¬ã»ãã¿
ã該ã¬ã©ã¹ã«å ±æçµåããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
ã第ïŒïŒé ã®ããããïŒé ã«èšèŒã®è©Šè¬ãããã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/291,354 US4447528A (en) | 1981-08-10 | 1981-08-10 | Detecting intrinsic factor blocking site antibody |
US291354 | 1981-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5838862A JPS5838862A (ja) | 1983-03-07 |
JPH0220068B2 true JPH0220068B2 (ja) | 1990-05-08 |
Family
ID=23119967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57139110A Granted JPS5838862A (ja) | 1981-08-10 | 1982-08-10 | èªå·±é®ææäœã®æ€ç¥æ¹æ³ãšè©²æ¹æ³ã«çšããããè©Šè¬ããã |
Country Status (4)
Country | Link |
---|---|
US (1) | US4447528A (ja) |
JP (1) | JPS5838862A (ja) |
FR (1) | FR2511155B1 (ja) |
GB (1) | GB2104216B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2181840B (en) * | 1985-10-16 | 1989-11-29 | Farmos Group Ltd | Method for the immunoassay of a macromolecular analyte |
US5506109A (en) * | 1989-06-26 | 1996-04-09 | Bayer Corporation | Vitamin B12 assay |
DE69008178T2 (de) * | 1989-06-26 | 1994-10-06 | Tritech Partners | Analyse von vitamin b12. |
US5310656A (en) * | 1989-06-26 | 1994-05-10 | Tritech Partners | Vitamin B12 assay |
US6942977B1 (en) | 1991-04-09 | 2005-09-13 | Bio-Rad Laboratories, Inc. | Immunoassays for determining vitamin b12, and reagents and kits therefor |
US6613535B1 (en) * | 1992-10-29 | 2003-09-02 | Becton, Dickinson Andcompany | HLA-B27 assay |
US5290706A (en) * | 1992-11-10 | 1994-03-01 | Camiener Gerald W | Visualization system for retrieval, identification, and positioning of biological samples for subsequent microscopic examination |
DE4328070C1 (de) * | 1993-08-20 | 1994-11-24 | Henning Berlin Gmbh | Verfahren zur Bestimmung eines Analyten in einem Volumen einer flÌssigen Probe sowie seine Anwendung zur Bestimmung von anti-TSH-Rezeptor-Autoantikörpern in einem Patientenserum |
US20050158812A1 (en) * | 2004-01-16 | 2005-07-21 | Gomez Elizabeth A. | Kits and methods for autoantibody detection |
US7790363B2 (en) | 2005-02-07 | 2010-09-07 | Abbott Laboratories Inc. | Diagnostic test for vitamin B12 |
US8288124B2 (en) * | 2008-11-20 | 2012-10-16 | Abbott Laboratories | Cloning, expression and purification of recombinant porcine intrinsic factor for use in diagnostic assay |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3615222A (en) * | 1968-09-04 | 1971-10-26 | New England Nuclear Corp | Method and apparatus for measuring the amount of a component in a biological fluid |
NL154600B (nl) * | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3721528A (en) * | 1970-06-04 | 1973-03-20 | L Mead | Method and apparatus for measuring the amount of a component in a biological fluid |
US4069352A (en) * | 1976-07-02 | 1978-01-17 | Baxter Travenol Laboratories, Inc. | Immunoadsorbent polymeric material and method of making same |
US4279859A (en) * | 1977-07-21 | 1981-07-21 | Becton Dickinson & Company | Simultaneous radioassay of folate and vitamin B12 |
US4292403A (en) * | 1978-08-24 | 1981-09-29 | Akzona Incorporated | Detection and/or determination of IgM, IgA, IgD and IgE immunoglobulins |
US4292296A (en) * | 1978-09-12 | 1981-09-29 | Baxter Travenol Laboratories, Inc. | Diagnostic method |
US4279886A (en) * | 1979-01-02 | 1981-07-21 | University Patents, Inc. | Test for pancreatic exocrine function |
DE2930706A1 (de) * | 1979-07-28 | 1981-02-05 | Medac Klinische Spezialpraep | Verfahren zum nachweis von erregerspezifischen antikoerpern |
-
1981
- 1981-08-10 US US06/291,354 patent/US4447528A/en not_active Expired - Lifetime
-
1982
- 1982-08-09 GB GB08222901A patent/GB2104216B/en not_active Expired
- 1982-08-09 FR FR8213853A patent/FR2511155B1/fr not_active Expired
- 1982-08-10 JP JP57139110A patent/JPS5838862A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5838862A (ja) | 1983-03-07 |
US4447528A (en) | 1984-05-08 |
FR2511155A1 (fr) | 1983-02-11 |
FR2511155B1 (fr) | 1985-08-23 |
GB2104216A (en) | 1983-03-02 |
GB2104216B (en) | 1984-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4273867A (en) | Method and reagent for counteracting lipemic interference | |
US4338094A (en) | Macroencapsulated immunosorbent assay technique | |
JPS6022662A (ja) | æäœãæåãŸãã¯æäœïŒæåè€åäœåæçšè©Šè¬ | |
EP0157797A1 (en) | Detecting an immunological reaction with activated red blood cells (erythrocytes) | |
JP2001502795A (ja) | è¡æ¶²åæåããã³æäœã®æ€åºã«æçšãªæ¹æ³ããã³è£ 眮 | |
JPH08501145A (ja) | åºçžå ç«åŠçæ€å®æ³ | |
JPH0220068B2 (ja) | ||
EP0194156B1 (en) | Method of measuring the amount of immune antibody in serum | |
EP0108992B1 (en) | Immunoassay | |
EP1709451B1 (en) | Reducing time to result for blood bank diagnostic testing | |
EP3508849A1 (en) | Antibody measurement method using antigen-carrying insoluble carrier particles on which antigen is immobilized by different methods, and reagent for antibody measurement | |
EP0253270B1 (en) | Method for diagnostic immunoassay by solid phase separation | |
JPH1114627A (ja) | å ç«åŠç蚺æè©Šè¬ | |
JP2004144687A (ja) | ç©è³ªã®æž¬å®æ¹æ³ | |
JP3618797B2 (ja) | å ç«æž¬å®æ³ | |
JP2001330614A (ja) | çç©æŽ»æ§ãä»äžããåºçžããã³ãã®è£œé æ¹æ³ | |
EP0206779A1 (en) | Detecting antinuclear antibody | |
JPH08327629A (ja) | æ€äœååŠçæ¹æ³ | |
JP3444649B2 (ja) | å ç«æž¬å®çšè©Šè¬ããã³ãã®è£œé æ¹æ³ | |
JPH05203642A (ja) | ããã¯ãã³æ¯æ¿èšã·ã¹ãã ãžã®äœ¿çšã®ããã®æ°èŠæã¹ãã¬ãããªãžã³âïœè©Šè¬ | |
JP3359415B2 (ja) | æãªã³è質æäœæž¬å®çšå ç«èšºæè¬ã®è£œé æ¹æ³ | |
JPH03103195A (ja) | è¡æ åã³ååºäº¢é²ç¶æ ã®èšºæåã³æ€æ»ã®ããã®çç©åŠçè©Šæããã®ïœâãã€ããŒã®çŽæ¥ååŠçµåçæ¹æ³ | |
JP3487651B2 (ja) | å ç«èšºæè©Šè¬ã®è£œé æ¹æ³ | |
JPH07270423A (ja) | å ç«èšºæè¬ã®è£œé æ¹æ³ | |
JP2000329768A (ja) | å ç«æž¬å®è©Šè¬åã³å ç«æž¬å®è©Šè¬ã®è£œé æ¹æ³ |